MapLight Therapeutics Stock
MapLight Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Christopher A. Kroeger
- Employees
- 133
- Market cap
- $328 M
- IPO
- 24/10/2025
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic…
MapLight Therapeutics stock: price history
1D
-4.0%
1W
-12.8%
1M
-32.5%
6M
-74.4%
YTD
-56.2%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
03/12/2026 (in 47 days)
Volatility around earnings
~36% weaker price swings than usual
Ask the agents about MapLight Therapeutics
Analyst assessment of MapLight Therapeutics
PRICE TARGET LOW
US$13.00
CONSENSUS
US$29.20
MEDIAN
US$28.00
PRICE TARGET HIGH
US$46.00
0
STRONG BUY
5
BUY
2
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 31/08/2026
MapLight Therapeutics stock metrics
P/E
-1.49
P/B
1
EV/EBITDA
-1.11
RETURN ON EQUITY
-17.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
18.7%
FLOAT SHARES
7,967,295
AVG. DAILY VOLUME (30D)
474,764
Insider transactions (SEC)
Lillie James Woodruff
Foff Erin Pennock
Kreitzer Anatol
Hanson Kristopher
Kroeger Christopher A.
Institutional holders
Comparable stocks
Frequently asked questions about MapLight Therapeutics stock
What does MapLight Therapeutics do?
MapLight Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Christopher A. Kroeger, the company employs around 133 people.
The IPO was on 24/10/2025; the stock trades on NASDAQ under the ticker MPLT.
What do analysts say about MapLight Therapeutics stock?
7 analysts rate the stock, the consensus is Buy (as of 31/08/2026).
The average price target is US$29.20, ranging from US$13.00 to US$46.00, with a median of US$28.00.
This is an external assessment, not a statement by Market Jury.
When does MapLight Therapeutics report next?
The next earnings date is 03/12/2026.
Around past earnings, price swings were roughly -36% stronger than usual.
Does MapLight Therapeutics pay a dividend?
No, MapLight Therapeutics currently does not pay a dividend.
Which stocks are comparable to MapLight Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MapLight Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess MapLight Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.